Antipolymer antibody in Italian fibromyalgic patients
2007

Antipolymer Antibody in Italian Fibromyalgia Patients

Sample size: 285 publication Evidence: moderate

Author Information

Author(s): Bazzichi Laura, Giacomelli Camillo, De Feo Francesca, Giuliano Tiziana, Rossi Alessandra, Doveri Marica, Tani Chiara, Wilson Russell B, Bombardieri Stefano

Primary Institution: University of Pisa, Pisa, Italy

Hypothesis

Does the presence of antipolymer antibodies correlate with disease severity and cytokine levels in fibromyalgia patients?

Conclusion

Antipolymer antibodies cannot be considered a marker of disease in Italian fibromyalgia patients, but their presence may help identify patients with more severe symptoms.

Supporting Evidence

  • 21.05% of fibromyalgia patients tested positive for antipolymer antibodies.
  • Patients with moderate and severe symptoms had slightly higher levels of antipolymer antibodies.
  • Significant correlations were found between antipolymer antibody levels and the Fibromyalgia Impact Questionnaire scores.

Takeaway

This study looked at a blood test for a specific antibody in fibromyalgia patients to see if it relates to how bad their symptoms are. It turns out the antibody isn't a good marker for the disease, but it might help find patients who are more affected.

Methodology

The study measured antipolymer antibody levels in serum samples using an ELISA kit and assessed cytokine levels and disease severity through questionnaires and scales.

Potential Biases

Potential bias may arise from the exclusion of certain patient groups, which could affect the results.

Limitations

The study excluded patients with silicone breast implants, which may limit the generalizability of the findings.

Participant Demographics

The study included 285 patients, predominantly female (270 females, 15 males), with a median age of 54 years.

Statistical Information

P-Value

P = 0.042 for correlation with Fibromyalgia Impact Questionnaire

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/ar2285

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication